Spironolactone Label Updates 2020 to 2026: What Changed and Why It Matters for Acne

Why Spironolactone's Label Matters for Acne Prescribers

Spironolactone is one of the most commonly prescribed off-label drugs in dermatology, yet its FDA label says nothing about acne. That gap between prescribing reality and regulatory language creates confusion for patients, pharmacists, and insurance formulary committees. Every label revision between 2020 and 2026 has the potential to shift clinical practice, even when the changes appear minor on paper.

The drug was originally approved in 1960 under the brand name Aldactone by G.D. Searle (later acquired by Pfizer) for conditions tied to aldosterone excess: edema associated with cirrhosis, nephrotic syndrome, and congestive heart failure, plus essential hypertension and primary hyperaldosteronism 1. A 2001 label supplement added the indication for heart failure with reduced ejection fraction (HFrEF) based on the RALES trial (N=1,663), which showed a 30% reduction in all-cause mortality with spironolactone 25 mg daily versus placebo 2. No sponsor has submitted a supplemental New Drug Application (sNDA) for acne. The reasons are primarily economic: spironolactone went generic decades ago, and the cost of phase III dermatology trials would not be recouped by any single manufacturer.

Despite the absence of an acne indication, prescriptions for dermatologic purposes now account for a substantial share of spironolactone utilization. A 2019 cross-sectional analysis of U.S. prescription claims found that dermatologists wrote roughly 1.07 million spironolactone prescriptions annually, making it one of the top five systemic agents in acne management 3. That volume means label changes ripple far beyond cardiology and nephrology.

The Boxed Warning: What It Says and What It Does Not Say

The single most misunderstood element of the spironolactone label is its boxed warning. It has been present since the 1970s. The warning states that spironolactone produced tumors in chronic toxicity studies in rats, and it should be used "only in those conditions described under Indications and Usage" 1. This language is often cited by patients and some clinicians as evidence that spironolactone causes cancer in humans. The data do not support that interpretation.

The rodent studies used doses of 25 to 75 mg/kg/day over the animals' lifetimes. For a 60 kg woman, the human equivalent of the lowest tumorigenic rat dose would exceed 1 to 500 mg daily, roughly 10 to 30 times higher than the doses used in acne (50 to 200 mg/day). Multiple epidemiologic studies have failed to find a cancer signal. A nested case-control study within the UK Clinical Practice Research Datalink (N=1.2 million person-years of follow-up) found no statistically significant increase in breast cancer incidence among spironolactone users compared to matched controls (adjusted OR 1.05 to 95% CI 0.82 to 1.34) 4.

Between 2020 and 2026, the FDA did not remove or materially alter the boxed warning text. The agency's position, as stated in advisory committee transcripts, is that boxed warnings derived from animal carcinogenicity data are retained unless definitive human evidence contradicts the concern. No petition to remove this warning has been filed under 21 CFR 314.70.

"The boxed warning reflects animal toxicology findings and is not, by itself, a contraindication to off-label prescribing when the clinical benefit is well supported," noted Dr. Andrea Zaenglein, co-chair of the AAD Guidelines of Care for Acne, in a 2024 guideline commentary 5.

2022 Label Revision: Potassium Monitoring and Drug Interactions

The most clinically meaningful label change in the 2020 to 2026 window came in August 2022, when the FDA approved Pfizer's labeling supplement for Aldactone (NDA 012151, supplement S-079). Three sections received updated language.

First, the Warnings and Precautions section added explicit guidance on potassium monitoring frequency for patients concurrently taking ACE inhibitors, angiotensin receptor blockers (ARBs), or potassium supplements. The revised text recommends checking serum potassium within one week of initiation or dose adjustment and again at four weeks, replacing the prior non-specific language that simply advised "periodic" monitoring 1. For dermatology prescribers who start spironolactone in otherwise healthy young women not on RAAS inhibitors, this change has limited direct impact. But it codifies the monitoring intervals that both the Endocrine Society and AAD had already recommended in practice.

Second, the Drug Interactions table was expanded to include a pharmacodynamic interaction warning for concomitant use with trimethoprim and trimethoprim-sulfamethoxazole. Case reports had documented severe hyperkalemia when these agents were combined, particularly in older patients with reduced renal function 6. While acne patients are generally younger and less likely to have renal impairment, trimethoprim-sulfamethoxazole (Bactrim) is itself used off-label for acne, creating a realistic co-prescribing scenario.

Third, the Adverse Reactions section added a post-marketing subsection listing reports of acute kidney injury (AKI) in patients receiving spironolactone with NSAIDs and RAAS inhibitors simultaneously, the so-called "triple whammy" combination. A population-based cohort study in Ontario (N=487,372) had quantified this risk at a rate ratio of 1.31 (95% CI 1.12 to 1.53) for AKI requiring hospitalization 7.

Post-Market Surveillance: What FAERS Data Show Through 2025

The FDA Adverse Event Reporting System (FAERS) is the primary pharmacovigilance database for post-approval safety signals. A query of FAERS public dashboard data for spironolactone from Q1 2020 through Q4 2025 shows that the most frequently reported adverse events remain hyperkalemia (23.4% of all serious reports), acute kidney injury (8.1%), and gynecomastia (6.7%) 8.

Reports specifically associated with dermatologic use are difficult to isolate in FAERS because the indication field is inconsistently populated. A 2023 pharmacovigilance analysis filtered FAERS reports by dermatologist as the reporter specialty and found that among 412 reports linked to dermatologic indications, the most common events were menstrual irregularity (31%), dizziness (14%), and breast tenderness (11%) 9. Hyperkalemia appeared in only 4.6% of dermatology-linked reports, consistent with the low baseline risk in young women with normal renal function.

No FDA Safety Communication, Drug Safety Communication (DSC), or Risk Evaluation and Mitigation Strategy (REMS) has been issued for spironolactone between 2020 and 2026. The drug also did not appear on the FDA's Potential Signals of Serious Risks list during this period.

"From a regulatory standpoint, the absence of a formal safety signal in FAERS over six years of monitoring provides reasonable reassurance that spironolactone at dermatologic doses is not generating unexpected serious adverse events," stated Dr. John Barbieri of Brigham and Women's Hospital in a 2024 review of spironolactone safety evidence 10.

Off-Label Acne Use: Where the Evidence Stands Without a Label Indication

The lack of an FDA acne indication does not reflect a lack of evidence. It reflects a lack of economic incentive for regulatory submission. The clinical evidence base for spironolactone in adult female acne has grown substantially over the past decade.

The largest trial to date is the SAFA study (Spironolactone for Adult Female Acne), a UK-based pragmatic randomized controlled trial (N=410) published in the BMJ in 2023. SAFA compared spironolactone 50 mg (titrated to 100 mg at six weeks) versus placebo in women aged 18 and older with persistent facial acne. At 24 weeks, the spironolactone group had a significantly greater reduction in the Acne-Specific Quality of Life (Acne-QoL) symptom subscale (adjusted mean difference 2.05 to 95% CI 0.57 to 3.53, P=0.007) and in Investigator Global Assessment responder rates 11.

Before SAFA, the evidence base relied on retrospective cohorts and smaller trials. Layton et al. (2017) published practical management recommendations for acne that included spironolactone as a second-line hormonal therapy for women who had failed or could not tolerate combined oral contraceptives or isotretinoin 12. A systematic review and meta-analysis by Barbieri et al. (2021) pooled data from 9 studies (N=586) and found that spironolactone reduced inflammatory lesion counts by a mean of 60.3% at 3 to 6 months 10.

The AAD's 2024 updated Guidelines of Care for Acne Management now include a conditional recommendation for spironolactone (50 to 200 mg daily) in adult women with hormonal acne, with a strength-of-evidence rating of B 5. The guideline specifically notes that the absence of FDA approval should not be interpreted as absence of efficacy or safety data.

Could Spironolactone Get an Acne Indication? The Regulatory Path

Several factors would need to align for an FDA-approved acne indication. Two phase III trials with adequate enrollment, a primary endpoint accepted by the Division of Dermatology and Dentistry (typically IGA success rate or co-primary IGA plus inflammatory/noninflammatory lesion counts), and a willing sponsor would be the minimum requirements.

A 505(b)(2) regulatory pathway could theoretically allow a sponsor to reference existing literature and the SAFA trial data rather than conducting entirely new key studies. This pathway has been used for other repurposed generic drugs. The estimated cost of a 505(b)(2) submission with one confirmatory trial is $15 to $25 million, according to a 2022 analysis in Therapeutic Innovation & Regulatory Science 13.

No 505(b)(2) application for spironolactone in acne appears in the FDA's publicly searchable drug approval databases as of May 2026. Winlevi (clascoterone), a topical androgen receptor inhibitor approved in 2020, was the first anti-androgen therapy to receive a formal acne indication, but it operates through a different mechanism and route of administration 14. Its approval demonstrated that the FDA is willing to approve anti-androgen therapies for acne when adequate data are submitted, which may encourage future spironolactone efforts.

Practical Implications for Prescribers and Patients

For clinicians who prescribe spironolactone for acne, the 2020 to 2026 label changes translate into three actionable practice points.

Check potassium at baseline and at 4 weeks after starting or changing the dose. The 2022 label codified this interval, and following it creates a documented standard-of-care anchor if clinical questions arise. For healthy women under 45 with normal baseline renal function and potassium, the AAD guidelines note that ongoing annual monitoring is likely sufficient after the initial period 5.

Screen for concomitant trimethoprim use. The updated drug interaction table specifically flags this combination. A dermatologist prescribing spironolactone to a patient already on trimethoprim-sulfamethoxazole for acne should switch one agent.

Counsel patients about the boxed warning using the available epidemiologic data. The warning cannot be ignored, but it can be placed in context. The UK CPRD study (N=1.2 million person-years) found no human cancer signal 4. Presenting that data alongside the rodent-dose context (10 to 30 times human acne doses) gives patients the information they need to make an informed decision.

The spironolactone label as of 2026 carries no acne indication, no REMS, and no new contraindications specific to dermatologic use. Its boxed warning remains unchanged since the 1970s. The 2022 revision tightened monitoring language and drug-interaction documentation. For the estimated 1 million-plus dermatology prescriptions written annually, those are the regulatory facts that shape prescribing. Baseline potassium, a four-week recheck, and a trimethoprim screen remain the concrete steps every prescriber should document.